Fisher Wallace Review: FDA-Cleared CES for Depression, Anxiety and Insomnia (Plus the OAK)

⚕️ Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. The Fisher Wallace Stimulator is an FDA-cleared medical device requiring a prescription. OAK is not yet FDA-cleared as of mid-2026. Always consult a qualified healthcare provider before using any device for anxiety, depression, or insomnia.

Fisher Wallace is one of the most interesting and complicated stories in the anxiety device space. Their original device — the Fisher Wallace Stimulator — is FDA-cleared for depression, anxiety, and insomnia, used by over 100,000 patients, and backed by genuine clinical research. Their next-generation device, OAK, was designed in collaboration with the engineers behind Beats and Nest, has Harvard Medical School modeling behind it, and is being piloted in the US Department of Veterans Affairs. It’s also not yet available for purchase and is still awaiting FDA clearance.

Understanding what Fisher Wallace actually is in 2026 requires understanding both devices — and the important transition currently underway between them.

📖 Two Devices, One Company: V1 vs OAK

The Fisher Wallace Stimulator (Current — Available Now)

The Fisher Wallace Stimulator is a Cranial Electrotherapy Stimulation (CES) device — the same technology category as Alpha-Stim. It delivers low-level electrical current through sponge electrodes placed on the temples for 20 minutes once or twice daily. It stimulates alpha wave production, increases serotonin and melatonin production, lowers cortisol, and calms the Default Mode Network — the brain’s rumination center. It is FDA-cleared for the treatment of depression, anxiety, AND insomnia, and requires a prescription in the US.

OAK (Next Generation — Not Yet Available)

OAK is Fisher Wallace’s next-generation headset — 17 years of R&D in a device designed by Eric Fields, who previously designed the first Nest thermostat and the Beats Pill. In 2025, researchers at Harvard Medical School and Massachusetts General Hospital modeled OAK’s neurostimulation, demonstrating it significantly engages brain structures governing mood, sleep, autonomic function, and cognitive regulation. It is currently being pilot-tested in the US Department of Veterans Affairs.

Important: OAK is not yet FDA-cleared and not yet available for purchase as of mid-2026. Fisher Wallace anticipates FDA clearance for anxiety in Q3 2026, with insomnia and depression to follow in 2027. Do not let OAK marketing drive a V1 purchase decision — they are different products at different stages.

Background reading: Wearable Anxiety Devices — All Options Compared

📊 The Clinical Evidence

The Fisher Wallace Stimulator has been used in 3 randomized controlled trials for depression and pain conditions, per an NCBI systematic review of CES devices — fewer than Alpha-Stim’s 12 RCTs in the same analysis, but meaningful clinical validation. A pivotal Major Depressive Disorder clinical trial completed in late 2022 showed preliminary results with active treatment superior to placebo and no serious adverse events. Most patients in clinical practice and trials report meaningful symptom relief within the first two weeks of daily use.

🆚 Fisher Wallace vs Alpha-Stim

• 📋 FDA clearance: Fisher Wallace — depression, anxiety, insomnia. Alpha-Stim — anxiety and insomnia only (not depression) in the US
• 🔬 Evidence depth: Alpha-Stim has more independent RCTs and the Lancet Psychiatry trial; Fisher Wallace has 3 RCTs
• 💰 Price: Fisher Wallace ~$599 vs Alpha-Stim AID ~$795
• 🩺 Electrodes: Fisher Wallace — temple sponges moistened with water. Alpha-Stim — earclip pads moistened with water
• ⚠️ Side effects: Both rare and mild — Fisher Wallace reports 1 in 500 users experience headache; 1 in 250 experience increased wakefulness

Background reading: Do Anti-Anxiety Devices Really Work? The Science Explained

✅ What Fisher Wallace Does Well

• ✅ FDA-cleared for depression, anxiety, AND insomnia — broadest clearance scope of any CES device
• 💰 Lower price than Alpha-Stim — $200 less for the equivalent indication
• 🎖️ Veteran and first responder discount — ~$499 for military, police, fire, EMT, and Medicare/Medicaid
• 💊 Strong patient reports for anxiety and insomnia — particularly among patients reducing benzodiazepine dependence under medical supervision
• 🚀 OAK pipeline is compelling — Harvard modeling, VA pilot, and top-tier industrial design suggest the next device could be genuinely significant

❌ The Honest Downsides

• 🔬 Smaller evidence base than Alpha-Stim — 3 vs 12 RCTs in the major systematic review; less independently validated
• 🛠️ Durability complaints — BBB and Trustpilot include multiple reports of devices failing; particularly problematic given the depression/anxiety indication
• ⏳ OAK production delays — early investors and crowdfunding backers have experienced repeated timeline shifts; trust has been tested
• 📋 Prescription required — adds friction vs wellness-only devices; telehealth options available
• 🤷 Variable individual response — a meaningful minority report limited benefit; 30-day return policy provides a safety net

👤 Who Is Fisher Wallace Best For?

• People with depression alongside anxiety and insomnia who want FDA-cleared device coverage for all three
• Veterans and first responders — meaningful discount and VA pilot testing track record
• Anyone for whom price is the deciding factor between the two major FDA-cleared CES options
• Those excited about the OAK roadmap and wanting to support the company’s development

💲 Pricing and How to Get It

• 📦 Fisher Wallace Stimulator (V1): ~$599 — visit fisherwallace.com
• 🎖️ Discounted ~$499 for veterans, active military, first responders, Medicare/Medicaid
• 📋 Prescription required in the US — doctor or telehealth via Fisher Wallace website
• 🔁 30-day return policy
• 🚀 OAK: Not yet available; anticipated FDA clearance Q3 2026
• 🏥 May be covered by insurance — verify with your provider

⭐ StopAnxiety.org Verdict

The Fisher Wallace Stimulator is a legitimate, FDA-cleared CES device with real clinical evidence and a genuine track record. Its broader FDA clearance scope — covering depression, anxiety, and insomnia together — is a meaningful advantage. The lower price and veteran discounts add to its case.

The honest comparison: if evidence depth is paramount, Alpha-Stim has a stronger independent research base. If clearance breadth and price matter more, Fisher Wallace makes a compelling case. Both are serious devices in a category where most competitors have far less validation.

OAK is genuinely exciting — but buy the V1 on its own merits, not OAK’s promise.

Rating: 4.6 / 5 — FDA-cleared for all three major indications, real clinical evidence, accessible pricing, and a strong pipeline. Slightly behind Alpha-Stim on evidence depth; ahead on clearance breadth and price. Durability concerns and OAK delays are worth watching.

Also on StopAnxiety.org:

• Alpha-Stim Review — FDA-Cleared CES Device for Anxiety and Insomnia
• Apollo Neuro Review — Does This Anxiety Wearable Actually Work?
• Sensate Review — Does This Vagus Nerve Device Actually Work?
• Pulsetto Review — Is This Vagus Nerve Stimulator Worth It?
• Wearable Anxiety Devices — All Options Compared
• Do Anti-Anxiety Devices Really Work? The Science
• Tools & Devices Hub — All Articles

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. The Fisher Wallace Stimulator is FDA-cleared and requires a prescription in the US. OAK is not yet FDA-cleared. Always consult a qualified healthcare provider before starting any new treatment. Individual results vary.